LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension

G. Simonneau, A. M. D¿Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. Wilkins, A. Fritsch, N. Davie, P. Colorado, E. Mayer (Le Kremlin¿Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; London, United Kingdom; Prague, Czech Republic; La Jolla, United States Of America; Beijing, China; Barcelona, Spain)

Source: International Congress 2014 – New technologies and biomarkers in lung disease
Session: New technologies and biomarkers in lung disease
Session type: Poster Discussion
Number: 1802
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Simonneau, A. M. D¿Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. Wilkins, A. Fritsch, N. Davie, P. Colorado, E. Mayer (Le Kremlin¿Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; London, United Kingdom; Prague, Czech Republic; La Jolla, United States Of America; Beijing, China; Barcelona, Spain). LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension. Eur Respir J 2014; 44: Suppl. 58, 1802

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014


Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014



Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014

Long-term screening for pulmonary hypertension after pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014

Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

LATE-BREAKING ABSTRACT: Predicting CTEPH after acute pulmonary embolism
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015


CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014

Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014


Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension
Year: 2015

PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014